 |
|
Injectable, Sustained-Release Naltrexone for the Treatment of Opioid Dependence
A Randomized, Placebo-Controlled Trial
Sandra D. Comer, PhD;
Maria A. Sullivan, MD, PhD;
Elmer Yu, MD;
Jami L. Rothenberg, PhD;
Herbert D. Kleber, MD;
Kyle Kampman, MD;
Charles Dackis, MD;
Charles P. O’Brien, MD
Arch Gen Psychiatry. 2006;63:210-218.
Context Oral naltrexone can completely antagonize the effects produced by opioid agonists. However, poor compliance with naltrexone has been a major obstacle to the effective treatment of opioid dependence.
Objective To evaluate the safety and efficacy of a sustained-release depot formulation of naltrexone in treating opioid dependence.
Design and Setting Randomized, double-blind, placebo-controlled, 8-week trial conducted at 2 medical centers.
Participants Sixty heroin-dependent adults.
Interventions Participants were stratified by sex and years of heroin use ( 5 vs <5) and then were randomized to receive placebo or 192 or 384 mg of depot naltrexone. Doses were administered at the beginning of weeks 1 and 5. All participants received twice-weekly relapse prevention therapy, provided observed urine samples, and completed other assessments at each visit.
Main Outcome Measures Retention in treatment and percentage of opioid-negative urine samples.
Results Retention in treatment was dose related, with 39%, 60%, and 68% of patients in the placebo, 192 mg of naltrexone, and 384 mg of naltrexone groups, respectively, remaining in treatment at the end of 2 months. Time to dropout had a significant main effect of dose, with mean time to dropout of 27, 36, and 48 days for the placebo, 192 mg of naltrexone, and 384 mg of naltrexone groups, respectively. The percentage of urine samples negative for opioids, methadone, cocaine, benzodiazepines, and amphetamine varied significantly as a function of dose. When the data were recalculated without the assumption that missing urine samples were positive, a main effect of group was not found for any drugs tested except cocaine, where the percentage of cocaine-negative urine samples was lower in the placebo group. Adverse events were minimal and generally mild. This formulation of naltrexone was well tolerated and produced a robust, dose-related increase in treatment retention.
Conclusion These data provide new evidence of the feasibility, efficacy, and tolerability of long-lasting antagonist treatments for opioid dependence.
Author Affiliations: Division on Substance Abuse, New York State Psychiatric Institute, and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York (Drs Comer, Sullivan, Rothenberg, and Kleber); and Department of Psychiatry, University of Pennsylvania, and Department of Behavior Health, Philadelphia Veterans Affairs Medical Center, Philadelphia (Drs Yu, Kampman, Dackis, and O’Brien).
RELATED LETTERS
Lack of Information in Naltrexone Study
Darius A. Rastegar
Arch Gen Psychiatry. 2007;64(7):865.
EXTRACT
| FULL TEXT
Lack of Information in Naltrexone Study—Reply
Sandra D. Comer, Maria A. Sullivan, Elmer Yu, Jami L. Rothenberg, Herbert D. Kleber, Kyle Kampman, Charles Dackis, and Charles P. O’Brien
Arch Gen Psychiatry. 2007;64(7):865.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A 50-Year-Old Woman Addicted to Heroin: Review of Treatment of Heroin Addiction
O'Brien
JAMA 2008;300:314-321.
ABSTRACT
| FULL TEXT
Dopamine in Drug Abuse and Addiction: Results of Imaging Studies and Treatment Implications
Volkow et al.
Arch Neurol 2007;64:1575-1579.
ABSTRACT
| FULL TEXT
Lack of Information in Naltrexone Study
Rastegar
Arch Gen Psychiatry 2007;64:865-865.
FULL TEXT
Lack of Information in Naltrexone Study--Reply
Comer et al.
Arch Gen Psychiatry 2007;64:865-865.
FULL TEXT
Buprenorphine for the treatment of opioid dependence
Boothby and Doering
Am J Health Syst Pharm 2007;64:266-272.
ABSTRACT
| FULL TEXT
Clinical Advances in Pharmacological and Integrated Treatment Approaches for Alcohol and Drug Use Disorders
Dermatis and Galanter
Focus 2007;5:141-150.
ABSTRACT
| FULL TEXT
What's in a Word? Addiction Versus Dependence in DSM-V
FAINSINGER et al.
Am. J. Psychiatry 2006;163:2014-2014.
FULL TEXT
Relative Reinforcing Effects of Cocaine, Remifentanil, and Their Combination in Rhesus Monkeys
Winger et al.
J. Pharmacol. Exp. Ther. 2006;318:223-229.
ABSTRACT
| FULL TEXT
|
